Vadim Koshkin MD
@koshkin85
Followers
2K
Following
3K
Statuses
1K
Associate Professor of Clinical Medicine @UCSF @ucsfcancer focusing on GU Oncology. Alum of @ClevelandClinic @umichmedicine @UChiPritzker Tweet re GU oncology
San Francisco, CA
Joined April 2017
RT @sonpavde: #bladdercancer update- honored to present at the Florida Society of Clinical Oncology Puerto Rico Oncology Symposium Feb 2025…
0
14
0
Thank you @urotoday and @shilpaonc for highlighting our international clinical trial of Futibatinib+Pebrolizumab in #BladderCancer presented at @myESMO #ESMO2024
@y_loriot @ClaraHwangMD @nachoduranm via @urotoday
@PGrivasMDPhD
0
2
8
Pembro rechallenge for #BladderCancer pts published in @EUplatinum Pts with response stop Pembro👉PD👉resume Pembro Rechallenge works: ORR: 41% mOS: 26 mos 👇 Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urot... @urotoday @Uromigos
0
13
37
RT @DrChoueiri: #AUC3 #Miami25 #kidneycancer #bladdercancer @DrRanaMcKay @montypal @DrRosenbergMSK
0
15
0
RT @AndreaNecchi: Great lineup of superstars best seen from the podium #AUC3 @DrChoueiri @DrRanaMcKay @montypal @DrRosenbergMSK
https://t.c…
0
11
0
RT @TiansterZhang: First conference of 2025! Coming to consensus in #kidneycancer & #bladdercancer — lots to debate & discuss. Kudos @DrRan…
0
6
0
RT @PGrivasMDPhD: Fantastic to be in Miami with many friends #AUC3 meeting discussing “hot topics” in RCC & urothelial Ca! Great organizati…
0
7
0
RT @shilpaonc: @DrRanaMcKay @DrChoueiri @DrRosenbergMSK @montypal kick off the inaugural #AUC3 consensus meeting to brainstorm & develop gu…
0
12
0
Our latest #Unite publication in @EurUrolOncol led by🌟@Tanjin097 Biomarkers of EV outcomes: ⬆️TMB associated w improved OS while CDKN2A/CDKN2B alts w inferior PFS 👇 Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Pat... @urotoday
2
13
41
RT @oncodaily: FGFR inhibitors shaping the future of precision medicine - @drenriquegrande
@koshkin85 @sonpavde
0
2
0
RT @tompowles1: 1/3 TROPICS-4: sacituzimab govitecan vs chemotherapy in heavily pretreated UC #ESMOasia24 @PGrivasMDPhD. OS & PFS HR of 0.8…
0
48
0
Our recent @EUplatinum editorial with @sonpavde on the critical role of #FGFR inhibitors in #BladderCancer commenting on @UrogerliMD paper @UCSFCancer @ucsf @BladderCancerUS @urotoday @Uromigos 👇
2
13
38
RT @PGrivasMDPhD: Excited to see our work over many years in print: we evaluated neoadjuvant immunoTx stimulating innate (NK cells) & adapt…
0
1
0
RT @PTarantinoMD: Could ADCs be safely administered subcutaneously? - clinical data of a sc ADC (JSKN003) just presented at #SITC2024, wit…
0
25
0
RT @PBarataMD: I am thrilled to endorse our wonderful colleagues @PGrivasMDPhD and @DrRanaMcKay for the @ASCO Board Directors. Their commi…
0
13
0
Looking forward to this meeting in Pasadena Nov 1-2 chaired by @PGrivasMDPhD with great colleagues and friends to discuss updates in GU and #BladderCancer
Join us on Saturday Nov 2 in Pasadena with stellar Faculty covering GU cancers @EfstathiouEleni @siadaneshmand @PBarataMD @koshkin85 #JulieGraff Multi-D discussions! There are still slots for Urologists to register: @l_ballas @TDorffOnc @AbhiTrip87
0
1
5
RT @TumorBoardTues: #TumorBoardTuesday 👏It is amazing how many HER2🎯💊options there are for metastatic bladder cancer 📢Join us Tuesday, 10…
0
10
0
RT @tompowles1: Just out. Ipi/nivo didn’t hit OS in cisplatin ineligible or PD-L1 +ve in 1st line UC in CM901. Surprising? Durva/treme (als…
0
54
0
@onder_haka2124 @tompowles1 Pts with DM are a challenging population for EV Rx, but it is not a contraindication. They should be monitored carefully while on EV and baseline blood sugar control should be tightened. BG > 250 is holding parameter. Data and clinical exp suggests EV is feasible for these pts.
1
0
2
@onder_haka2124 @tompowles1 We do have some data from the Unite study just presented at #ESMO2024 that prior DM (and/or neuropathy) at baseline do not predispose patients to have inferior outcomes with EV monotherapy. It seems these patients do just as well with EV
1
0
1